We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Par’s Investigation Analysis Is Lacking, 483 Says
Par’s Investigation Analysis Is Lacking, 483 Says
January 4, 2010
Par Pharmaceutical has received three Form 483 observations related to GMP deviations, including failure to review unexplained discrepancies in batches.